ArticleBMC pulmonary medicine2026
The association between sarcopenia and peak expiratory flow decline in middle-aged and older adults: a nationwide cross-sectional and longitudinal study in China.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundEvidence suggests an association between sarcopenia and impaired respiratory function; however, longitudinal population-based data on the relationship between sarcopenia, its individual components, and peak expiratory flow (PEF) decline remain limited. This study aimed to investigate the cross-sectional and longitudinal associations of sarcopenia and its components with PEF measures among middle-aged and older Chinese adults.
methodsData were obtained from the 2011 and 2015 waves of the China Health and Retirement Longitudinal Study (CHARLS). Sarcopenia was defined according to the Asian Working Group for Sarcopenia 2019 criteria. Cross-sectional associations between sarcopenia and PEF measures were examined using multivariable logistic and linear regression models. Longitudinal associations between baseline sarcopenia and subsequent PEF decline were evaluated using multivariable logistic regression models.
resultsA total of 9452 participants were included in the cross-sectional analysis. Compared with participants without sarcopenia, those with sarcopenia and severe sarcopenia had higher odds of severe airflow limitation (SAL) (OR = 1.41, 95% CI: 1.20-1.65 and OR = 1.56, 95% CI: 1.26-1.94, respectively). Sarcopenia and its individual components were also associated with lower PEF and PEF% predicted. In the longitudinal analysis of 4804 participants, low muscle strength was the strongest and most consistent predictor of subsequent PEF decline. Participants with low muscle strength had a higher risk of new-onset SAL (OR = 1.54, 95% CI: 1.20-1.98) and a 56%-64% greater risk of PEF% predicted decline across different thresholds. Severe sarcopenia and low muscle mass were also associated with greater risks of moderate-to-severe PEF% predicted decline.
conclusionSarcopenia was associated with poorer cross-sectional PEF measures, whereas low muscle strength showed the strongest and most consistent longitudinal associations with subsequent PEF decline. These findings highlight the potential importance of muscle strength preservation for maintaining respiratory health in middle-aged and older adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.